Related Experiment Video
Updated: Jan 7, 2026

An In Vitro Dissolution Determination of Multi-Index Components in Tibetan Medicine Rhodiola Granules
Published on: November 4, 2022
Patent Term Extension for Innovative Drugs in China: A Cohort Study from 2021 to 2024
Xuefang Yao1, Yan Zhang2, Jin Zhou2
1School of Health Economics and Management, Nanjing University of Chinese Medicine, Nanjing, Jiangsu Province, China. sarina_yao@126.com.
Background:
In January 2024, China officially implemented the patent term extension (PTE) system, that is, began to implement PTE for innovative drugs approved after June 1, 2021. This study analyzed the PTE system's outcomes in China and its potential impact on drug accessibility.
Methods:
We conducted a simulation analysis of the PTE duration and effective patent life after listing (EPLL) of innovative drugs approved by Chinese regulatory authorities from June 2021 to December 2024, using data collected from public databases such as China's marketed drug patent registration platform.
Results:
A total of 148 innovative drugs were included in the study. Among them, 61% were able to obtain PTE, with a median PTE duration of 5 years (IQR: 2.3-5). The median EPLL before adding PTE was 9 years (IQR: 6.1-11.7), and the median EPLL after adding PTE was 14 years (IQR: 11.1-14), an increase of 55.6%. Furthermore, the study reveals variations across drug types and therapeutic areas.
Conclusions:
Compared to findings from prior studies on the U.S. and the European Union, the median PTE duration for innovative drugs in China is longer, while the median EPLL is only marginally extended. Both Chinese domestic stakeholders and foreign enterprises should evaluate the potential impact by considering both the incremental PTE periods and the overall EPLL levels.
More Related Videos
09:16Author Spotlight: Optimization of Processing Technology for Tiebangchui with Zanba Based on CRITIC Combined with Box-Behnken Response Surface Method
Published on: May 12, 2023
10:21Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
Published on: February 23, 2024
Related Concept Videos
FDA Approved Drugs: Changes to Approved Drugs
Clinical Trials: Overview
Drug Products: Biologics, Biosimilars and Interchangeables
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Bioequivalence studies: Biowaivers
Bioavailability Enhancement: Drug Permeability Enhancement